Trial of the Week: CHAMPION PHOENIX

Pharmacy to Dose: The Critical Care Podcast

Contenuto fornito da Nick Peters. Tutti i contenuti dei podcast, inclusi episodi, grafica e descrizioni dei podcast, vengono caricati e forniti direttamente da Nick Peters o dal partner della piattaforma podcast. Se ritieni che qualcuno stia utilizzando la tua opera protetta da copyright senza la tua autorizzazione, puoi seguire la procedura descritta qui https://it.player.fm/legal.

1M ago 1:00:35

MP3•Pagina principale dell'episodio

Trial of the Week: CHAMPION PHOENIX

Special Guest: Jack Pluenneke, PharmD, BCCP @JackPluenneke

Jack Pluenneke joins to discuss a March 2024 Trial of the Week, “Effect of platelet inhibition with cangrelor during PCI on ischemic events” the CHAMPION PHOENIX trial, published in 2013 in NEJM.

We review PK/PD advantages with cangrelor, go over the CHAMPION trials, and then highlight why the CHAMPION PHOENIX trial was necessary. Then we dive into the Trial of the Week: CHAMPION PHOENIX trial and discuss its findings as well as study design. Are these patients we’d see in our ICU? How does cangrelor compare to glycoprotein 2b/3a inhibitors? Is it a weakness that the comparator group uses clopidogrel? The episode closes with medication safety considerations, cangrelor’s place in therapy, and much more.

Reference list: https://pharmacytodose.files.wordpress.com/2024/03/champion-phoenix-trial-of-the-week-references-1.pdf

PharmacyToDose.Com

@PharmacyToDose

PharmacyToDose@Gmail.com

Learn more about your ad choices. Visit megaphone.fm/adchoices

148 episodi

#Fitness #Nick Peters #Medicine #Science #Special Guests #Pharmacy